No OS Benefit With Gefitinib vs Chemo for EGFR + NSCLC No OS Benefit With Gefitinib vs Chemo for EGFR + NSCLC

Adjuvant gefitinib provides no overall survival benefit over standard chemotherapy for EGFR-mutant, resected, stage II-IIIA non – small cell lung cancer (NSCLC), according to results from the ADJUVANT trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news